Inclusion Criteria:

          1. Adult males and females, 40+ years in general good health as assessed by the
             investigator.

          2. BCC (subtype: superficial or nodular) confirmed histologically by diagnostic shave
             biopsy at the Screening Visit

          3. Primary BCC (i.e., no previous treatment)

          4. Lesion size ≥ 4 mm2 or 2 x 2 mm and ≤ 169 mm2 or 13 x 13 mm

          5. Participant must have no other "clinically significant" abnormal findings in his/her
             medical history, physical examination or clinical laboratory test results as assessed
             by the investigator

          6. Negative urine pregnancy at study entry for female of child bearing potential

          7. Men and women of child-producing potential must agree to use adequate contraception
             according to standard instructions by the investigator until the completion of the
             study

          8. Participant must to be willing to adhere to the instructions of the investigator and
             his or her research team

          9. Participant must sign an Informed Consent Form prior to any study specific procedures
             and entry into the study

        Exclusion Criteria:

          1. Evidence of clinically significant, unstable medical conditions as assessed by the
             investigator

          2. Excisional biopsy performed on the lesion to be treated in this study

          3. Recent therapy(ies) to the BCC treatment area

          4. Recurrent BCC (previously treated) at the site presented for treatment

          5. BCC lesion to be treated is located in an area where excisional biopsy is undesired or
             aesthetically unacceptable to the participant

          6. Previously demonstrated sensitivity to doxorubicin or carboxymethyl cellulose.

          7. Participant with other active malignancies with the exception of non-metastatic
             prostate cancer and carcinoma in situ of the skin and cervix

          8. Concomitant disease requiring systemic immunosuppressive treatment

          9. Genetic skin cancer disorder, e.g., basal cell nevus syndrome

         10. Participant is pregnant or breastfeeding

         11. Treatment with another investigational drug, device, or other intervention within 3
             months prior to the Screening Visit

         12. Existing condition or treatment within 3 months prior to the Screening Visit that may
             have impact on clinical outcome for the treatment of BCC or delay in wound healing
             from the elliptical excision